Skip to main content

Research Repository

Advanced Search

The role of neutralizing antibodies in hepatitis C virus infection

Edwards, Victoria C.; Tarr, Alexander W.; Urbanowicz, Richard A.; Ball, Jonathan K.

The role of neutralizing antibodies in hepatitis C virus infection Thumbnail


Authors

Victoria C. Edwards

Richard A. Urbanowicz

JONATHAN BALL jonathan.ball@nottingham.ac.uk
Professor of Molecular Virology



Abstract

Hepatitis C virus (HCV) is a blood-borne virus estimated to infect around 170 million people worldwide and is, therefore, a major disease burden. In some individuals the virus is spontaneously cleared during the acute phase of infection, whilst in others a persistent infection ensues. Of those persistently infected, severe liver diseases such as cirrhosis and primary liver cancer may develop, although many individuals remain asymptomatic. A range of factors shape the course of HCV infection, not least host genetic polymorphisms and host immunity. A number of studies have shown that neutralizing antibodies (nAb) arise during HCV infection, but that these antibodies differ in their breadth and mechanism of neutralization. Recent studies, using both mAbs and polyclonal sera, have provided an insight into neutralizing determinants and the likely protective role of antibodies during infection. This understanding has helped to shape our knowledge of the overall structure of the HCV envelope glycoproteins -the natural target for nAb. Most nAb identified to date target receptor-binding sites within the envelope glycoprotein E2. However, there is some evidence that other viral epitopes may be targets for antibody neutralization, suggesting the need to broaden the search for neutralization epitopes beyond E2. This review provides a comprehensive overview of our current understanding of the role played by nAb in HCV infection and disease outcome and explores the limitations in the study systems currently used. In addition, we briefly discuss the potential therapeutic benefits of nAb and efforts to develop nAb-based therapies. © 2012 SGM.

Journal Article Type Review
Publication Date Jan 1, 2012
Deposit Date Nov 9, 2022
Publicly Available Date Nov 9, 2022
Journal Journal of General Virology
Print ISSN 0022-1317
Electronic ISSN 1465-2099
Publisher Microbiology Society
Peer Reviewed Peer Reviewed
Volume 93
Issue 1
Pages 1-19
DOI https://doi.org/10.1099/vir.0.035956-0
Public URL https://nottingham-repository.worktribe.com/output/3129511
Publisher URL https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.035956-0